N-{(R)-4-[4-(2-Fluoro-6-hydroxy-3-methoxy-benzoyl)-benzoylamino]-azepan-3-yl}-isonicotinamide; Dihydrochloride

ID: ALA1202518

Chembl Id: CHEMBL1202518

PubChem CID: 49860221

Max Phase: Preclinical

Molecular Formula: C27H29Cl2FN4O5

Molecular Weight: 506.53

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  COc1ccc(O)c(C(=O)c2ccc(C(=O)N[C@@H]3CCCNCC3NC(=O)c3ccncc3)cc2)c1F.Cl.Cl

Standard InChI:  InChI=1S/C27H27FN4O5.2ClH/c1-37-22-9-8-21(33)23(24(22)28)25(34)16-4-6-17(7-5-16)26(35)31-19-3-2-12-30-15-20(19)32-27(36)18-10-13-29-14-11-18;;/h4-11,13-14,19-20,30,33H,2-3,12,15H2,1H3,(H,31,35)(H,32,36);2*1H/t19-,20?;;/m1../s1

Standard InChI Key:  RULLUFJEKCEXEH-XGGJCEHPSA-N

Associated Targets(Human)

AKT1 Tchem Serine/threonine-protein kinase AKT (9192 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

PRKACA cAMP-dependent protein kinase A (41 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Mus musculus (284745 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 506.53Molecular Weight (Monoisotopic): 506.1965AlogP: 2.45#Rotatable Bonds: 7
Polar Surface Area: 129.65Molecular Species: BASEHBA: 7HBD: 4
#RO5 Violations: 1HBA (Lipinski): 9HBD (Lipinski): 4#RO5 Violations (Lipinski): 1
CX Acidic pKa: 6.88CX Basic pKa: 9.55CX LogP: 1.54CX LogD: 1.47
Aromatic Rings: 3Heavy Atoms: 37QED Weighted: 0.36Np Likeness Score: -0.34

References

1. Breitenlechner CB, Wegge T, Berillon L, Graul K, Marzenell K, Friebe WG, Thomas U, Schumacher R, Huber R, Engh RA, Masjost B..  (2004)  Structure-based optimization of novel azepane derivatives as PKB inhibitors.,  47  (6): [PMID:14998327] [10.1021/jm0310479]

Source